We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ewa Gogola

Wellcome Early Career Fellow & Nicholas Kurti JRF (Brasnose College)

I joined the Patel lab after completing my PhD at the Netherlands Cancer Institute in Amsterdam, the Netherlands, where I studied PARP inhibitor resistance in BRCA1/2-deficient cancers. I am currently a Wellcome Trust Early-Career Award Fellow investigating tissue-specific responses to endogenous DNA damage and their contributions to tissue homeostasis and ageing. I am particularly interested in DNA damage-induced whole genome duplication and polyploidy.

Recent publications

A histone deacetylase 3 and mitochondrial complex I axis regulates toxic formaldehyde production.

Wit N. et al, (2023), Sci Adv, 9

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Zingg D. et al, (2022), Nature, 608, 609 - 617

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

Paes Dias M. et al, (2021), Mol Cell, 81, 4692 - 4708.e9

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E. et al, (2019), Cancer Cell, 35, 950 - 952

Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer

Gogola E. et al, (2019), ANNUAL REVIEW OF CANCER BIOLOGY, VOL 3, 3, 235 - 254

More publications

Cookies on this website

Contact information

Research groups

Colleges